837 results on '"A. Nakagawa"'
Search Results
2. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
3. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
4. MO69-3 Pathological predictors of the response to platinum-based chemotherapy in pancreatobiliary neuroendocrine carcinoma
5. O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
6. MO31-5 A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
7. SY09-3 The role of fluoropyrimidines in HER2-negative early breast cancer
8. MO36-2 Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP)
9. MO38-2 Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations – final report
10. MO35-6 Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)
11. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701)
12. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
13. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
14. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
15. MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis
16. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
17. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
18. Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi
19. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
20. 1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)
21. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort
22. 975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
23. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
24. 958P Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L)
25. 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
26. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
27. 1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)
28. 982P Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
29. O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158
30. MO28-5 Clinical utility of comprehensive genomic profiling for patients with cancer of unknown primary site
31. MO44-4 Phase II study of nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616L
32. MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study
33. O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study
34. 132P The potential of VEGF-A in the peripheral blood serum as a biomarker of response in the addition of bevacizumab with chemotherapy-combined immunotherapy for metastatic nonsquamous non-small cell lung cancer
35. LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
36. 225P Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
37. 1789P Second OS interim analysis from BEAT-SC: A randomized phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)
38. 1478P Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
39. 1357P Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
40. 1220P A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC
41. 1208MO Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study
42. 1016P Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
43. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
44. 317P A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
45. Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi
46. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy
47. MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis
48. SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)
49. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
50. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.